天坛生物：慈翔辞去总法律顾问、首席合规官职务

Group 1 - The company TianTan Bio (SH 600161) announced the resignation of its General Counsel and Chief Compliance Officer, Ci Xiang, effective immediately upon delivery of her resignation to the board [1] - Following Ci Xiang's departure, the board of directors of the company's subsidiary, China National Pharmaceutical Group Xi'an Biological Pharmaceutical Co., Ltd., fell below the legal number of members, prompting Ci Xiang to continue serving as a director until a new director is elected [1] - For the first half of 2025, the company's revenue composition shows that the biopharmaceutical industry accounts for 99.68% of total revenue, while other businesses contribute 0.32% [1] - As of the report date, the market capitalization of TianTan Bio is 38 billion yuan [1] Group 2 - The competitive landscape in the beverage industry is highlighted by a significant market share decline for Yi Bao, which dropped nearly 5 percentage points following the launch of the Farmer Green Bottle [1]